30
/fr/
AIzaSyAYiBZKx7MnpbEhh9jyipgxe19OcubqV5w
June 15, 2024
3512562
319423
2
Public Timelines FAQ
Public TimelinesFAQ
Public TimelinesFAQ
For educational institutions For teachers For students Open cabinet
For educational institutions For teachers For students Open cabinet
Créer
Create a timeline
Public timelines
Library
FAQ

1 janv. 2013 - Ado-Trastuzumab Emtansine (T-DM1)

Description:

For the treatment of patients with HER2-positive breast cancer previously treated with trastuzumab and/or a taxane drug, the FDA recommends ado-trastuzumab emtansine (T-DM1).

Ajouté au bande de temps:

Cancer

ByTrinity Ozias
14 nov. 2019
0
0
203

Date:

1 janv. 2013
Maintenaint
~ Il y a 11 ans
About & FeedbackUn accordConfidentialitéBibliothèque
2024 © Time.Graphics
Support 24/7  
CabinetGet premium
Donate
The service accepts bank transfer (ACH, Wire) or cards (Visa, MasterCard, etc). Processed by Stripe.
Secured with SSL
Excellent (Trustpilot Reviews)
Based on 115+ reviews